Anixa Biosciences Inc (ANIX) SEC 13F Holdings (Q2 2026) — Net Institutional Activity: $865.4K

ANIX ranks #5479 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

67 institutions disclose a position in ANIX, but none treat it as a major bet — even Laird Norton Wetherby Trust Company, LLC, its most concentrated holder, allocates just 0.0% of its own portfolio to it.

CoreCap Advisors, LLC has added to its ANIX position for two straight quarters, increasing it by $47.5K to reach $181.7K today.

ANIX reported a net loss of $10.4M over the trailing twelve months.

• Not yet profitable — net loss of $10.4M over the trailing twelve months
• Revenue declined 59.2% year over year
• Net income improved year over year, from -$11.1M to -$10.4M
• Operating cash flow was negative, using $7.2M in cash
• Current ratio of 8.08x — enough short-term assets to cover short-term liabilities
• Liabilities run 6.45x equity — a highly leveraged balance sheet worth noting